Tyme Technologies (NASDAQ: TYME) and Bioverativ (NASDAQ:BIVV) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.
Insider & Institutional Ownership
2.4% of Tyme Technologies shares are owned by institutional investors. Comparatively, 100.0% of Bioverativ shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Tyme Technologies and Bioverativ’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a summary of current ratings and price targets for Tyme Technologies and Bioverativ, as provided by MarketBeat.
||Strong Buy Ratings
Tyme Technologies currently has a consensus target price of $8.25, suggesting a potential upside of 140.52%. Bioverativ has a consensus target price of $63.25, suggesting a potential downside of 39.07%. Given Tyme Technologies’ stronger consensus rating and higher possible upside, equities analysts clearly believe Tyme Technologies is more favorable than Bioverativ.
Valuation & Earnings
This table compares Tyme Technologies and Bioverativ’s revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Bioverativ has higher revenue and earnings than Tyme Technologies. Tyme Technologies is trading at a lower price-to-earnings ratio than Bioverativ, indicating that it is currently the more affordable of the two stocks.
Bioverativ beats Tyme Technologies on 8 of the 10 factors compared between the two stocks.
Tyme Technologies Company Profile
Tyme Technologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and it is preparing to initiate an additional Phase II clinical trial for pancreatic cancer. The Company provides a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers including breast, lung, prostate, gastric, esophageal and pancreatic cancers.
Bioverativ Company Profile
Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person’s blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.